KEY POINTS Several therapies targeting the androgen receptor and other pathways have improved survival and quality of life for patients with metastatic prostate cancer. Many costly therapeutic clinical trial efforts have failed to improve outcomes. Prostate cancer is a complex disease. Its biologic heterogeneity warrants that future clinical trials be carefully designed to achieve higher levels of clinical impact by attention to targeting more critical pathways; integrating improved diagnostics; well-designed and powered clinical trials using multi-targeted strategies; and optimized timing of therapy.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: